资讯

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...
▎药明康德优于现有疗法!Moderna流感mRNA疫苗3期结果积极Moderna今日公布其季节性流感mRNA疫苗mRNA-1010在3期临床研究(P304)积极进展。该研究在50岁及以上的成人群体中评估了mRNA-1010相较于获批标准剂量季节性流感 ...
Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.
Moderna 的季节性流感 mRNA 疫苗 mRNA-1010 在 III 期试验中展现出显著优势 —— 在 50 岁及以上人群中,其预防流感的效果比现有标准剂量疫苗高出 26.6%。这项覆盖 11 个国家、超 4 万名受试者的研究显示,65 岁以上老年人群的保护效力提升更为明显,达 27.4%。细分病毒株数据进一步验证其优势:对 A/H1N1 株保护效力提高 29.6%,A/H3N2 株提高 ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
近年来,流感疫苗的研发一直是公众和医学界关注的热点。随着Moderna公司最新的季节性流感mRNA疫苗mRNA-1010在III期临床试验中取得显著成果,流感疫苗的未来似乎迎来了新的曙光。这项覆盖11个国家、超过4万名受试者的研究结果显示,mRNA-1010在50岁及以上人群中的预防效果比现有的标准剂量疫苗高出26.6%。对于65岁以上的老年人群体,其保护效力更是提升至27.4%。这一数据不仅让人 ...
周二,美股医药板块逆市走高,截至发稿,Moderna (MRNA.US)涨超1.6%,礼来 (LLY.US)涨0.85%,诺和诺德 (NVO.US)涨超1.2%,联合健康 (UNH.US)涨超3.9%,辉瑞 (PFE.US)涨超3.4%。消息面上,此前Moderna宣布其mRNA流感疫苗 ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna美股盘前涨超6%。 一周牛熊股丨15股周涨超40%,最牛股周涨超95% 一周牛熊股丨15股周涨超40%,最牛股周涨超95% 一周牛熊股 ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...